Randomized Phase II Study of Carboplatin and Paclitaxel With Either Linifanib or Placebo for Advanced Nonsquamous Non–Small-Cell Lung Cancer

PURPOSE: Linifanib, a potent, selective inhibitor of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors, has single-agent activity in non–small-cell lung cancer (NSCLC). We evaluated linifanib with carboplatin and paclitaxel as first-line therapy of advance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Ramalingam, Suresh S., Shtivelband, Mikhail, Soo, Ross A., Barrios, Carlos H., Makhson, Anatoly, Segalla, José G.M., Pittman, Kenneth B., Kolman, Petr, Pereira, Jose R., Srkalovic, Gordan, Belani, Chandra P., Axelrod, Rita, Owonikoko, Taofeek K., Qin, Qin, Qian, Jiang, McKeegan, Evelyn M., Devanarayan, Viswanath, McKee, Mark D., Ricker, Justin L., Carlson, Dawn M., Gorbunova, Vera A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2015
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5478045/
https://ncbi.nlm.nih.gov/pubmed/25559798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.55.7173
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados